Off-Label Use: When Medications Go Beyond Approved Indications

Case Study...

A doctor prescribes propranolol, a classic medication for hypertension and arrhythmias, to a weeks-old infant with a growing hemangioma. The official drug information makes no mention of hemangiomas. Yet, this approach can align with current medical knowledge and is legal in most healthcare systems. This is off-label use, applying a drug outside its registered indications.

There are many misconceptions surrounding this term. The most common one is that off-label use is either illegal or experimental. Neither of these descriptions is accurate. Off-label simply means that a particular use of the drug has not undergone the formal registration process for that specific indication. The drug is approved, available on the market, and has its registered information. It’s just being used in a way not specified in the registration documents.

What Exactly Does Off-Label Mean?

The European Medicines Agency defines off-label use as the use of a drug for an unapproved indication, in an unapproved age group, dosage, or route of administration. The U.S. FDA describes it similarly and adds a practical principle: once a drug is approved, a physician may use it off-label if they deem it medically appropriate for the patient.

The reference point is always the official, approved drug information. The names of these documents vary by region. In the European Union, it’s the Summary of Product Characteristics (SmPC); in the United States, it’s the label and prescribing information; and in Australia and Canada, it’s the Product Information or product monograph. The mechanism is the same everywhere: the document specifies the approved uses, target populations, and administration methods for the drug. Anything outside this scope is considered off-label.

There are two important distinctions that are often confused. First, off-label use is not the same as using an unlicensed drug. An off-label drug is approved and available in pharmacies but is used outside its approved scope. An unlicensed drug, on the other hand, is not registered in a given country and is typically used only under exceptional circumstances, such as clinical trials or individual access programs. This boundary is clearly outlined in a comprehensive review of the practical aspects of off-label use.

Second, off-label use is a deliberate action with a therapeutic intent. This sets it apart from medical errors, which are unintentional, and drug misuse, which lacks therapeutic intent. The EMA’s definition of intentional use for medical purposes excludes mistakes and misuse from this category, as explained in the EU’s legal framework on off-label use.

Four Dimensions Where a Drug Goes Beyond Its Registration

Off-label use always involves deviating from one of the four parameters outlined in the approved drug information. The Australian regulator (TGA) defines it clearly: off-label use refers to applications that do not align with the indications, dosages, routes of administration, or patient groups specified in the registered information. In practice, this means:

A different medical indication than the one registered.
A different patient group than the one covered by the registration, often including children, pregnant women, or the elderly.
A different dose, frequency, or duration of treatment.
A different route or form of administration.

Along this axis lies a spectrum of evidence. In some cases, robust research supports a given off-label use, but the manufacturer has not submitted an application to expand the registration. In other cases, evidence is scarce, and the use borders on experimental. The weaker the evidence, the greater the responsibility on the prescriber.

Why Off-Label Doesn't Mean Illegal

The key is simple and consistent across various jurisdictions. Regulatory agencies evaluate a drug before it enters the market and oversee its advertising, but they do not regulate medical practice itself. Manufacturers are prohibited from promoting off-label uses, but physicians make therapeutic decisions based on their knowledge and professional standards. Let’s take a look at how this works in different systems:

United States. The FDA traditionally does not regulate medical practice, so a physician can prescribe an approved drug for an indication that the FDA has not evaluated. However, state laws and professional licensing scopes may set boundaries.
European Union. Off-label use is not harmonized at the EU level and is treated as a prescriber’s decision rather than a systemic issue, as confirmed by the European Commission’s analysis under the STAMP program.
Canada. Health Canada does not regulate off-label use, and prescribing practices fall under the jurisdiction of provincial and territorial medical boards.
Australia. Using a drug beyond its approved indications is legal and considered a form of drug repurposing.

Interestingly, even the definition of off-label use is not standardized. A survey of five agencies—FDA, EMA, Health Canada, the UK’s MHRA, and Australia’s TGA—revealed the absence of a uniform, formal definition of off-label use in pediatrics. The takeaway for readers is that while specifics vary by location, the overarching principle of separating drug registration from medical practice is universally upheld.

Who is Responsible and Under What Conditions

Legality does not exempt one from responsibility; in fact, it often increases it. The prescribing professional is accountable for the consequences of administering a drug outside its approved indications. This is why similar safeguards are emphasized across various healthcare systems. Canadian professional guidelines recommend obtaining the patient's informed consent and reporting adverse effects resulting from off-label use. Physician protection organizations also stress the importance of closely monitoring patients receiving off-label medications.

How Common Is This Phenomenon?

Off-label use is not a fringe aspect of medicine; it is part of everyday practice, especially in areas where regulatory studies are lacking.

In general, U.S. data has shown that off-label use accounts for approximately 21 percent of prescriptions for 160 popular drugs. A Canadian study based on electronic patient records estimated the frequency of off-label use at 11 percent, with 79 percent of such prescriptions lacking strong scientific evidence. The difference in numbers highlights how much the results depend on the methodology and the group of drugs analyzed.

The most striking example involves children. A meta-analysis of 45 studies conducted between 1990 and 2023 estimated the global prevalence of off-label and unlicensed prescriptions for children at around 56 percent, with rates ranging from 26 to 95 percent in neonates. An earlier EMA review indicated that 45 to 60 percent of prescriptions for children in the European Union were for off-label uses or unlicensed drugs. The reason is structural. Few clinical trials are conducted in children, and most drugs are approved primarily for adults.

Oncology presents a similar picture, where more than half of cancer drug applications are off-label. In pediatric oncology, a large U.S. center reported that off-label use of targeted therapies involved 9.2 percent of patients under the age of 30, with this percentage increasing over time.

Propranolol: The Story of an Accidental Discovery

The best example of how off-label use can revolutionize medicine is propranolol. In 2008, French dermatologist Christine Léauté-Labrèze and her team administered this drug to children with hemangiomas due to cardiac issues. They observed something unexpected: the hemangiomas regressed rapidly and noticeably. They documented this series of cases in the New England Journal of Medicine, opening a new chapter in the treatment of hemangiomas, as detailed in an NCBI publication on the diagnosis and treatment of infantile hemangiomas.

For several years, propranolol in hemangioma treatment was purely off-label. A drug known for decades as a cardiac medication was being used for a new indication, initially based on observations and later supported by research. Randomized data showed that approximately 60 percent of patients responded to treatment, with tumor regression occurring within six months. It wasn't until March 2014 that the FDA approved oral propranolol for infantile hemangiomas, completing the journey from accidental observation to official indication.

The story carries an important lesson for understanding the phenomenon as a whole. Off-label use often serves as the frontier where medicine tests new applications for existing molecules before regulatory systems catch up. However, it can also be a minefield, as the same serendipitous observations may not always hold up. In the case of propranolol, the findings were confirmed, but the drug is not without its known side effects, including drops in blood pressure, bradycardia, and hypoglycemia, as highlighted in analyses of its mechanism of action in hemangiomas.

Covering Costs Is a Separate Matter

Here lies a trap that many patients around the world encounter. Just because a doctor can legally prescribe a drug off-label doesn’t mean that a public payer or insurer will cover its cost. The ability to prescribe and the right to reimbursement are two distinct issues, decided separately and often vary greatly depending on the healthcare system.

In the United States, the decision is made by payers, and in oncology, off-label uses are sometimes covered based on recognized compendia, as described in a Congressional report on off-label use.

In Australia, registration by the TGA is one thing, but subsidization under the PBS reimbursement program is a completely separate decision.

In Canada, public and private payers reimburse off-label drug use inconsistently, despite the lack of comprehensive regulatory oversight for such applications.

The practical takeaway is simple. If a particular use isn’t covered for reimbursement in a given system, the patient may have to pay the full price for the drug, even if the prescription is entirely clinically justified.

Risks to Keep in Mind

Off-label use, by definition, relies on weaker evidence compared to approved indications. In cases where off-label use lacks solid data support, there is a higher incidence of adverse effects. The Canadian study mentioned earlier revealed that nearly four-fifths of off-label prescriptions were not backed by strong evidence. This is not an argument against off-label use itself, but rather against using it hastily without assessing the benefit-risk ratio.

For patients, there are three practical takeaways. First, they have the right to know that a medication is being prescribed off-label and to ask what evidence supports this decision. Second, informed consent is not a formality but a critical element of safety. Third, the lack of reimbursement does not mean the therapy is inferior, only that it is not covered by the funding system for this indication.

Checklist: When Off-Label Use is Justified

A practical set of questions to guide your decision-making, regardless of the country or which side of the desk you're on:

Is there a registered alternative with proven efficacy for this indication?
Is the off-label use supported by reliable data rather than isolated reports?
Has the patient been informed and provided informed consent?
Is the issue of cost reimbursement clear, and does the patient know if they will need to pay for the medication?
Does the use fall within recognized practice, or is it part of scientific research with its own specific protocols?

What It Means at the Pharmacy Counter

From the perspective of working in a pharmacy, off-label use is more common than the average patient might think. A prescription for an antiepileptic drug to treat neuropathic pain, low doses of an antidepressant for insomnia, or a beta-blocker for tremors or anxiety—all of these are examples of off-label use. A patient reads the leaflet, doesn't see their condition listed, and comes back asking if the pharmacist made a mistake. Most of the time, there’s no mistake—it's a deliberate decision by the doctor based on current medical knowledge. The role of the person dispensing the medication is to calmly explain that the leaflet describes the approved indications, not all permissible uses, and to redirect any concerns back to the prescribing doctor.

The content is for informational and educational purposes only. It does not replace the advice of a doctor or pharmacist and is not an individual therapeutic recommendation. The legal status and reimbursement rules for off-label use vary between countries, so details should be verified according to the regulations applicable in your jurisdiction. The decision to use a medication, including off-label, is made by a doctor based on the patient's complete clinical picture.

About the Author. This text was prepared by a pharmacy technician with over a decade of experience in the pharmaceutical sector (medications, dietary supplements, medical devices), combining hands-on pharmacy practice with a background in IT. Specializes in translating pharmacological and regulatory topics into language that is accessible to patients.

Content Review Date. May 2026.